Clinical Trials Sponsored by Vanesa Pavlotsky

Total 278 results

University of Jyvaskyla
Vanha Vaasa Hospital

Not yet recruiting

The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Psychotic Depression | Delusional Disorder
Vanesa Abuín
Universidad Europea de Madrid

Completed

Effectiveness of the Neural Mobilization on Upper Limb Functionality in Patients With Acquired Brain Injury

Acquired Brain Injury | Hemiplegia and Hemiparesis

Spain
Vantia Ltd

Completed

VA106483 Dose Response Study in Elderly Males

Nocturia

United States
Vantia Ltd

Completed

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Nocturia

United States
Vantia Ltd

Completed

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

Primary Dysmenorrhea

United States, United Kingdom
Saneso Inc.

Completed

Case Series With Saneso 3600 Colonoscope

Colonic Neoplasms

United States
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Vantia Ltd

Completed

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

Healthy

Germany
Vantia Ltd

Completed

Efficacy Study of VA106483 in Males With Nocturia.

Nocturia

United States
Vantia Ltd

Completed

VA106483 Dose Response in Females

Nocturia

United States
Vantia Ltd

Completed

VA106483 and Alpha Blocker Interaction Study in Elderly Males

Nocturia

United Kingdom
Kanisa Pharmaceuticals

Completed

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid
Vanessa Olbrecht

Enrolling by invitation

Recruitment and Behavioral Economic Strategies

Surgery | Adolescent Behavior

United States
Vantia Ltd

Completed

Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon

Nocturia

Germany
Vantia Ltd

Completed

Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)

Nocturia | Benign Prostatic Hypertrophy (BPH)

Germany
Vantia Ltd

Completed

VA111913 TS: First in Human Study

Dysmenorrhea

United Kingdom
Kanisa Pharmaceuticals

Completed

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Leukemia, Myeloid
Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (COV-COMPARE)

SARS-CoV-2 Virus Infection

United Kingdom
Valneva Austria GmbH

Active, not recruiting

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Chikungunya

United States
Kaneka Corporation
ClinSearch

Unknown

Post Market Clinical Follow-Up for ED Coil / Electro-detach Generator v4

Arteriovenous Malformations | Aneurysm | Arterio-venous Fistula

Germany, Belgium
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Healthy

Austria, Germany
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Recruiting

A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years

Chikungunya Virus Infection

Dominican Republic, Honduras
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

SARS-CoV-2 Virus Infection

New Zealand
Valneva Austria GmbH

Completed

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Valneva Austria GmbH

Completed

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Clostridium Difficile

Germany, United States
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
Valneva Austria GmbH

Completed

An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Clostridium Difficile Infection

Austria, Hungary
Valneva Austria GmbH

Withdrawn

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Japanese Encephalitis

United Kingdom
Valneva Austria GmbH

Completed

Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

Chronic Hepatitis C
Valneva Austria GmbH

Completed

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

Pneumonia, Ventilator-Associated

Austria
Valneva Austria GmbH

Recruiting

A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)

Chikungunya Virus Infection

Panama
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

SARS-CoV-2 Infection

New Zealand, Netherlands
Valneva Austria GmbH

Withdrawn

COVID-19 Paediatric VLA2001-321 Study

SARS-CoV-2 Infection
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Valneva Austria GmbH

Completed

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

Pseudomonas Aeruginosa Infection

Spain, Germany, Belgium, Austria, Czech Republic, Hungary
Valneva Austria GmbH

Completed

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Japanese Encephalitis

Philippines
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria

3

Subscribe